Arthritis Drugs In the Medical Literature This Month

Journal: Nature Clinical Practice: Cardiovascular Medicine 2005 Jun; 2(6):290-300

Authors: G. Spektor, V. Fuster

Summary: The authors review past and forthcoming data regarding the cardiovascular risk of COX-2 inhibitors, placing particular focus on Vioxx and Celebrex. They state, however, that while an adverse class effect is a possibility for COX-2 inhibitors, published data are so far inconsistent, adding that baseline cardiovascular risk might contribute significantly to the inconsistent findings. The paper also refers to recent studies suggesting an improvement …